BA
The Boeing Company
BA has a slight edge over RXO overall, supported by lower modeled downside and stronger fundamentals.
RXO
RXO, Inc.
RXO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
RXO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Weak |
RXO's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
RXO PE Valuation
RXO has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 54x next year's earnings.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
RXO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect RXO to return to profit, with revenue growing. However, they disagree widely on these estimates.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has the edge over RXO on earnings quality, reporting a profit while its opponent remains loss making.
RXO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.52 | — |
| Q3 2026 | -$0.52 | -$0.04 |
| Q2 2026 | -$0.62 | +$1.59 |
| Q1 2026 | -$0.62 | +$1.60 |
| Q4 2025 | -$0.59 | +$1.58 |
| Q3 2025 | -$0.48 | +$1.51 |
| Q2 2025 | -$2.21 | -$2.02 |
| Q1 2025 | -$2.22 | -$2.12 |
| Q4 2024 | -$2.17 | -7333% |
RXO is still losing money, but far less than before: $0.52 per share over the past year, against $2.22 at its worst in early 2025.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA's revenue has grown year over year for seven quarters in a row: $24.2B last quarter, up 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA has the edge over RXO on profitability, with a higher operating margin.
RXO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +32% |
| Q2 2026 | $1.8B | +25% |
| Q1 2026 | $1.4B | -0.6% |
| Q4 2025 | $1.5B | -12% |
| Q3 2025 | $1.4B | +37% |
| Q2 2025 | $1.4B | +53% |
| Q1 2025 | $1.4B | +57% |
| Q4 2024 | $1.7B | +70% |
RXO's revenue is growing: $1.9B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.9% | +1.4 points |
| Q2 2026 | 0.1% | +0.1 points |
| Q1 2026 | -2% | +0.1 points |
| Q4 2025 | -2.9% | -1.4 points |
| Q3 2025 | -0.5% | +1.4 points |
| Q2 2025 | 0% | 0 points |
| Q1 2025 | -2.1% | -0.8 points |
| Q4 2024 | -1.4% | -2.9 points |
RXO's operating margin was 0.9% last quarter, up 1.4 points from the same quarter a year ago.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over RXO on cash generation, producing positive trailing cash flow while its opponent burns cash.
RXO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12M | +33% |
| Q2 2026 | -$52M | -678% |
| Q1 2026 | -$24M | -$7M |
| Q4 2025 | -$9M | +$10M |
| Q3 2025 | $9M | +$27M |
| Q2 2025 | $9M | +$25M |
| Q1 2025 | -$17M | -$13M |
| Q4 2024 | -$19M | -2000% |
RXO's free cash flow was −$73M over the past year, against −$18M the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
RXO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +2.4M shares |
| 1 year | +2% | +3.4M shares |
| 3 years | +47% | +55M shares |
| 5 years | +49% | +56.9M shares |
RXO has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA has the edge over RXO on leverage, with a lower net debt burden relative to earnings.
RXO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.4x | High |
| Q2 2026 | 16.0x | High |
| Q1 2026 | 12.9x | High |
| Q4 2025 | 10.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 9.2x | High |
| Q1 2025 | 13.4x | High |
| Q4 2024 | 10.7x | High |
RXO's net debt is about 8.4 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
RXO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.7 | Neutral |
| Stochastic | 85.5 | Overbought |
RXO's weekly RSI is 61 (neutral) and its Stochastic is 85 (overbought).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
RXO PE vs Industrials Sector
| Metric | RXO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
RXO has no meaningful PE right now: it lost money over the past year.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
RXO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.6 | 6.3% above |
| 20 week MA | $24.6 | 15% above |
| 50 week MA | $20.4 | 38% above |
| 100 week MA | $18.9 | 49% above |
| 200 week MA | $20.6 | 37% above |
RXO has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
RXO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $21.5 | $16.3 | -24% |
| 2023 | $16.3 | $23.3 | +43% |
| 2024 | $23.3 | $24.4 | +4.7% |
| 2025 | $24.4 | $12.7 | -48% |
| 2026 YTD | $12.7 | $28.3 | +123% |
RXO has the edge over BA on returns for 2026, with the stronger performance.